Syndax appoints Keith A. Goldan as CFO; base salary $450k, option for 230k shares

Syndax Pharmaceuticals Inc

Keith Goldan appointed CFO effective June 13, 2022; previously CFO at OptiNose.
Employment terms: $450k base salary, 40% target bonus, option for 230k shares (4-yr vest), $50k RSU sign-on.
Sharon Klahre named VP, Investor Relations and Communications, reporting to Goldan.
Goldan brings ~30 years biopharma CFO experience; co. expects multiple pivotal readouts in 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Keith A. Goldan

Chief Financial Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-06-13
Filed: June 13, 2022, 7:59 PM ET

On June 13, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Keith A. Goldan will join the Company as Chief Financial Officer, effective June 13, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith A. Goldan was appointed as Chief Financial Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 13, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Keith A. Goldan will join the Company as Chief Financial Officer, effective June 13, 2022.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001564590-22-023045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.